Onchilles Pharma Advancing Tumor-Killing Drug Candidate to the Clinic

University of Chicago spinout Onchilles Pharma plans to initiate first-in-human clinical trials next year for its lead drug candidate – which has demonstrated broad, potent, and direct tumor-killing activity. The…

Cancer’s Achilles’ Heel? UChicago Startup Secures $7 Million to Develop ‘Game-Changer’ Treatments

Onchilles Pharma recently closed its Series A funding round, bringing in approximately $7 million, including a $500,000 investment from the University of Chicago’s Startup Investment Fund. Cofounded by UChicago Associate…

Innovation Fund Invests $575,000 in Biotech Companies

The University of Chicago Innovation Fund announced plans to invest up to $575,000 into three biotechnology companies—ImmunArtes, Onchilles Pharma, and Oxalo Therapeutics. These latest investments bring the Innovation Fund’s total…

This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.

Accept